Early Returns From the Era of Precision Medicine

JAMA. 2020 Jan 14;323(2):109-110. doi: 10.1001/jama.2019.20659.

Author

David M Cutler¹

Affiliation

¹ Otto Eckstein Professor of Applied Economics in the Department of Economics and Kennedy School of Government at Harvard.

PMID: 31935015
DOI: 10.1001/jama.2019.20659

No abstract available

MeSH terms

Antineoplastic Agents / economics*
Cost-Benefit Analysis
Drug Approval
Drug Costs
Economic Competition
Humans
Insurance Coverage
Medical Oncology
Neoplasms / drug therapy*
Precision Medicine / economics*
United States

Substances

Antineoplastic Agents